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Summary 
The kinetics  of growth of two virulent strains of mycobacteria (M.  tuberculosis Erdman and 
M. tuberculosis H37Rv) and two attenuated strains (M. tuberculosis H37Ra and M. boris Bacillus 
Calmette-Guerin [BCG]) were studied in the lungs, livers, spleens, and kidneys of severe  combined 
immunodeficient (SCID) mice and of their coisogenic CB-17 immunocompetent counterparts. 
It was found, in keeping with the findings of earlier investigators (Pierce, C. H., R. J. Dubos, 
and W. B. Schaefer.  1953.J. Exp Med. 97:189.), that in immunocompetent  mice, virulent organisms 
grew progressively only in the lungs, whereas the growth of attenuated organisms was controlled 
in all organs. In SCID mice, in contrast, virulent mycobacteria grew rapidly and progressively in 
all organs, as did BCG, although at a slower rate. However, H37Ra failed to grow progressively in 
any organs of  SCID mice, unless the mice were treated with hydrocortisone. In fact, hydrocortisone 
treatment enabled virulent, as well as attenuated,  organisms to grow strikingly more rapidly in 
all organs of SCID mice and in all organs of CB-17 mice. A histological study showed that 
in SCID mice, multiplication of mycobacteria in the liver occurs in the cytoplasm of macrophages 
in granulomas and presumably in macrophages in other organs. It is suggested, therefore, that 
the macrophages of SCID mice possess a glucocorticoid-sensitive mycobacterial mechanism that 
prevents virulent and avirulent mycobacteria from expressing their true minimal doubling times. 
In the absence of this mechanism in the lungs of hydrocortisone-treated SCID mice, the doubling 
times of Erdman, H37Rv,  BCG,  and H37Ra were 17.7,  17.4, 44.6,  and 98.6 h, respectively. 
The possible importance of a rapid multiplication rate for mycobacterial virulence is discussed. 
S 
trains of Mycobacteria tuberculosis are considered virulent 
if they have been isolated from persons with active dis- 
ease and are capable of causing progressive infection in ex- 
perimental animals. Attenuated strains are derived from viru- 
lent ones and have lost the ability to grow progressively in 
animals. The suitability of mice for studying host resistance 
to virulent and attenuated strains of  mycobacteria  was demon- 
strated some time ago by Pierce et al. (1) who showed that 
standard strains considered virulent for humans are also viru- 
lent for mice, and that virulence is associated with the ability 
of these strains to grow progressively in the lungs,  rather 
than in other organs, regardless of the route of infection. At- 
tenuated strains, in contrast, were shown to be capable of 
only limited growth in all organs, presumably because of the 
growth inhibitory action of acquired immunity. 
It is now well established that the control and subsequent 
resolution of infection with attenuated mycobacteria, such 
as the attenuated strain of  Mycobacteria  boris, Bacillus  Calmette- 
Guerin (BCG) 1, is dependent on an acquired mechanism of 
cellular immunity that is predominantly mediated by CD4 + 
T cells. Evidence for this conclusion is seen in publications 
(2, 3) showing that mice selectively depleted of CD4 + T 
cells, but not CD8 + T cells, are rendered incapable of resolv- 
ing BCG infection, and that mice in the process of resolving 
BCG infection possess CD4 + T cells capable of transferring 
some level of  immunity to irradiated recipient mice (4). There 
is also evidence (5) that CD4 T cells are responsible for the 
limited antimycobacterial resistance offered by mice before 
succumbing to infection with virulent mycobacteria. It is ap- 
parent, therefore, that attenuation ofM. tubercu/osis  and M. bov/s 
is associated  with loss of ability to grow progressively in mice 
in the face of an acquired mechanism of T cell-mediated im- 
munity. 
Obviously, attenuated mycobacteria are of interest because 
of their possible usefulness as vaccines. For example, it has 
been shown (6, 7) that mice infected with BCG or attenu- 
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subsequent infection with virulent organisms. However, the 
ability of BCG to immunize humans is far less certain, in 
that its effectiveness in a number of vaccine trials has varied 
enormously, from providing 80% to zero protection (8). This 
has led some to suggest (8, 9) that more immunogenic BCG 
vaccines be developed,  perhaps with the aid of recombinant 
DNA technology. However, it might be premature to em- 
bark on a search for more immunogenic vaccines until it is 
first known whether lack of immunogenicity is the reason 
for the limited effectiveness of BCG as a vaccine.  It seems 
possible, until shown otherwise, that virulence of  M. tubercu- 
losis is based on an ability to avoid destruction by even high 
levels of acquired specific immunity. Therefore, a rational ap- 
proach to the design of an efficacious antituberculosis vac- 
cine will require  some understanding of the  meaning of 
mycobacterial virulence. 
It was with a view to understanding mycobacterial viru- 
lence that the study described here was undertaken. The results 
show, as an extension of the original findings of Pierce et 
al. (1), that virulent mycobacteria, in contrast to attenuated 
ones,  have the capacity to grow progressively in the lungs 
of mice in the face of an acquired mechanism of CD4 T 
cell-mediated immunity that is capable of controlling myco- 
bacterial  growth in other organs. It is shown, in addition, 
that virulent organisms have a faster doubling time than at- 
tenuated organisms in SCID mice, and an even faster dou- 
bling time in SCID mice whose immunological-independent 
defenses have been compromised by treatment with hydrocor- 
tisone. 
Materials  and Methods 
Mice.  CB-17  scid/scid (SCID) and coisogenic CB-17 mice were 
employed when they were 8 wk of age. They were supplied by 
the Trudeau Institute Animal Breeding Facility and were known 
to be free of common viral pathogens according to the results of 
routine screening performed by the Research Diagnostic Labora- 
tory, College of  Veterinary  Medicine, University  of Missouri. These 
mice were also free ofPneumocystis carinii as a result of having been 
bred from B and T cell-engrafted parents (10). They were housed 
in isolator cages supplied with filtered air, and provided with steri- 
lized food and water. 
Mycobacteria.  All strains of mycobacteria  were obtained from 
the Trudeau Mycobacterial Culture (TMC) Collection. Virulent 
strains employed  were M. tuberculosis Erdman (TMC No. 107) and 
M. tuberculosis  H37Rv (TMC No. 102). Both were supplied  as frozen 
(-70~  log-phase, dispersed cultures in Proskauer and Beck (P 
and B) medium (Dffco  Laboratories,  Detroit, MI) containing 0.01% 
Tween 80. To ensure virulence, the cultures were thawed and used 
to seed Tween 80-free P and B medium on which M. tuberculosis 
was allowed to grow as a surface  pellicle over several weeks of sub- 
culturing. The final  culture was homogenized in a glass tube fitted 
with a teflon pestle to break up bacterial rafts, and the homogenate 
used to seed a large volume of P and B medium containing 0.01% 
Tween 80 in which M. tuberculosis grew as a submerged, dispersed 
culture at 37~  The culture was harvested  towards the end of  log- 
phase growth and dispersed in 1-ml volumes that were frozen and 
stored at  -70~  to serve as stock cultures for experiments. For 
each experiment, a vial was thawed, subjected to 5 s of ultrasound 
to break up aggregates, diluted in PBS containing 0.01% Tween 
80, and 0.2 ml used to inoculate mice via a lateral tail vein. Attenu- 
ated strains employed  were M. tuberculosis H37Ra (TMC No. 201) 
and M. bovis BCG Pasteur (TMC No. 1011). These were also sup- 
plied as frozen log-phase cultures in P and B medium containing 
0.01% Tween 80. They were prepared for inoculation as described 
for virulent strains. All strains  were enumerated  in the lungs, kidneys, 
livers, and spleens of infected mice by preparing homogenates of 
these organs in PBS containing 0.05% Tween, and plating 10-fold 
serial dilutions of the homogenates on enriched agar (Middlebrook 
7Hll; Difco Laboratories). Colonies were counted after 3-4 wk 
incubation at 37~ 
T  Cell Depletion.  Mice  were depleted of CD4 T cells by in- 
jecting them intravenously  at the times of  infection indicated with 
0.5 mg of anti-CD4 mAb produced by hybridoma GK1.5 (TIB 
207; American Type Culture Collection, Rockville, MD). The hy- 
bridoma was grown as an ascites in immunodepressed mice, and 
the ascites was harvested  and the mAb purified according to proce- 
dures described previously (3). 
Cytofluorometry.  The SCID mouse  colony  was sampled  routinely 
to check for B and T cell "leakiness".  This involved  examining sus- 
pensions of LN cells with a FACScan  |  cytofluorometer (Becton 
Dickinson & Co., Mountain View, CA) after incubating the cells 
with FITC-conjugated F(ab')2 fragments of anti-CD4, anti-CDS, 
or anti-Ig mAbs according to procedures described  previously (3). 
Histology.  Small  pieces of livers were fixed overnight in 10% 
phosphate-buffered  formalin,  washed  for 2 h in tap water, dehydrated 
in 70 and 100% ethanol, and embedded  in glycol  methacrylate  0B-4 
embedding kit; Polysciences,  Inc., Warrington, PA) according to 
the suppliers instructions.  1-2-/~m sections were cut with glass 
knives using a ultramicrotome (Porter Blum MT-1; Sorvall, Inc., 
Newtown, CT). The sections  were stained  with Ziehl-Neelsen  stain, 
or with a phenol-crystal  violet stain (11) at 60~  followed  by brief 
decolorization with 95% ethanol. Micrographs were taken with 
a Nikon Microphot-Fx microscope. 
Hydrocortisone Acetate.  This was obtained as an emulsion from 
United Research Laboratories  (Philadelphia,  PA). It was given sub- 
cutaneously in a dose of 2.5 mg at 5-d intervals. 
Results 
Growth Potential of Virulent  Versus Attenuated Mycobacteria 
in SCID and CB-17 Mice.  Because specific immunity would 
be expected to restrict the growth of virulent and attenuated 
mycobacteria to different degrees, it was reasoned that a true 
comparison of the growth rates of these organisms in vivo 
can only be made by following their growth in mice that 
are incapable of generating specific immunity. Therefore, ex- 
periments were performed that compared the growth of at- 
tenuated and virulent mycobacteria in SCID mice, as well 
as in their immunocompetent CB-17 coisogenic counterparts. 
Figs.  1-4  show the growth of M.  tuberculosis  Erdman, 
M. tuberculosis H37Rv (virulent strains), M. tuberculosis H37Ra, 
and BCG  (attenuated strains),  respectively,  in  the lungs, 
kidneys,  spleens,  and livers of SCID and CB-17 mice over 
a 60-d period of infection. It can be seen that in CB-17 mice, 
the main difference between virulent and attennuated mycobac- 
teria was that the former, but not the latter organisms, grew 
progressively in the lungs. In the other organs of CB-17 mice, 
none of the strains grew progressively, although it is apparent 
that Erdman was the more virulent of the two virulent strains, 
1724  Mycobacterial  Virulence 6- 
10- 
z  4- 
z~ 
E3 
nr- 
LLI 
o2 
(.9  - 
0  12- 
8-  j 
I-- 
6- 
DEATH  LUNG 
D 
=--= CB-17 
a--o SClD 
12- 
10- 
8- 
4  I  I  I 
0  10  20  40 
SPLEEN 
--i 
KIDNEY 
/ 
--._,~ 
i 
,  I 
LIVER 
o 
I 
60 
DAYS 
i 
I  !  I  I 
10  20  40  60 
Figure  1.  Growth  of M.  tuberculosis Erdman  in the lungs,  kidneys, 
spleens, and  livers of SCID and  CB-17 mice inoculated  with 2  x  10  s 
bacilli i.v. Means  of five mice per time point. 
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Figure  2.  Growth  of M.  tuberculosis H37Rv in  the lungs,  kidneys, 
spleens, and livers of SCID and CB-17 mice inoculated  with 104 bacilli 
i.v. Means of five mice per time point. 
because its numbers plateaued, whereas those of H37Rv de- 
creased. Indeed, on the basis of its growth characteristics in 
the liver, spleen, and kidney, H37Rv appeared no more viru- 
lent than BCG or H37Ra. 
In SCID mice, the situation was different in that virulent 
strains grew rapidly and progressively in the liver, spleen, and 
kidneys, as well as in the lungs, although fastest in the lungs. 
BCG also grew progressively in all organs of SCID mice, 
but at a substantially slower rate than virulent strains.  It is 
obvious moreover, that BCG also grew fastest in the lungs, 
meaning that its growth, like that of virulent strains,  was 
more restricted in other organs in the absence of a specific 
immune response. H37Ra, on the other hand, failed to grow 
progressively in any organ of SCID mice, indicating the pos- 
sibility that in the absence of an immune response the growth 
of this organism was self-limiting. 
Control of  Growth of  H37Rv in the Livers, Spleens, and Kidneys 
of CB-17 Mice Is Dependent on CD4 T  Cells.  It is shown 
by the foregoing results that,  whereas growth of virulent 
mycobacteria in immunocompetent mice is progressive in the 
lungs, it is controlled in other organs after 10-20 d of infec- 
tion. This indicates that a mechanism of immunity is acquired 
in response to infection with virulent mycobacteria which 
is efficiently  expressed in all organs except the lungs. Because 
resolution of BCG infection has been shown to depend pre- 
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dominantly on the function of CD4 T  cells (2, 3), it was 
anticipated that this same subset of T  cells would prove to 
be necessary for control of infection with virulent organisms. 
That this is the case is shown in Fig. 5, where it can be seen 
that H37Rv-infected CB-17 mice injected intravenously with 
0.25 mg of anti-CD4 mAb on days 5,  10,  20,  30,  and 40 
of infection were greatly deficient in their capacity to inhibit 
the growth of this organism in their livers, spleens, and kidneys. 
Moreover, treatment with anti-CD4 mAb caused a substan- 
tial increase in the rate of growth of this organism in the 
lungs.  These  results  do  not  exclude the  participation  of 
CD8 §  T  cells and other T  cells in the immune response. 
Hydrocortisone Treatment  Enhances Growth Rates of  All Strains 
of Mycobacteria in SCID Mice.  The foregoing results show 
that virulent mycobacteria grow rapidly and progressively in 
all organs of SCID mice, indicating that there is little resis- 
tance offered to the growth of these organisms in the absence 
of acquired specific immunity. BCG also grew progressively 
in SCID mice, but more slowly, indicating that in the ab- 
sence of specific immunity it has a slower doubling time. 
Growth of H37Ra,  however, was inhibited in SCID mice 
at an early stage of infection, making it likely that an im- 
munologically independent mechanism of resistance is acquired 
that is capable of restricting the growth of this highly at- 
tenuated strain. If such a mechanism does develop, it is likely 9- 
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Figure  3.  Growth of M. boris BCG in the lungs, kidneys, spleens, and 
livers of mice inoculated  with 2  x  106 bacilli i.v. Means of five mice per 
time point. 
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Figure  5.  Exacerbation  of M.  tuberculosis H37Rv infection  in CB-17 
mice by intravenous  injection  of 0.5  mg of anti-CD4 mAb on days  5, 
10, 20, 30, and 45 of infection.  Control mice received equivalent amounts 
of rat IgG.  Infection  was initiated  with 2  x  10  ~ H37Rv  i.v.  Means  of 
five mice per group  per time interval. 
that it also serves to restrict the growth of virulent mycobac- 
teria in SCID mice. To investigate this possibility, the growth 
of virulent and avirulent organisms was followed in SCID 
mice treated with hydrocortisone. It was reasoned that, be- 
cause glucocorticoids  have been  shown to inhibit  the an- 
5- 
4- 
m  3-  rr 
p~ 
03 
t 
O2- 
~7-  o 
6- 
5- 
4- 
LUNG 
ring/  ￿9149  CB-17 
a--a SClD 
KIDNEY 
SPLEEN  LIVER 
/  ~-a  i~  1  ~-''--a/a~o- 
I  I  I  I  I  I  I  I 
10  20  40  60  0  10  20  40  60 
DAYS 
Figure  4.  Growth  of M.  tuberculosis H37Ra  in  the  lungs,  kidneys, 
spleens, and livers of mice inoculated  with 2  x  106 bacilli i.v.  Means of 
five mice per time point. 
timicrobial functions of macrophages in vitro (12, 13), these 
compounds  should also be capable of inhibiting  this func- 
tion of macrophages in vivo. 
The results in Table 1 show quite clearly with all mycobac- 
teria investigated that 2.5 mg of hydrocortisone given sub- 
cutaneously on days 5, 10, and 20 of infection caused a large 
increase in bacterial load in all organs of SCID and CB-17 
mice by day 25 of infection,  at which time some cortisone- 
treated SCID mice infected with virulent  strains began  to 
die. As an example of the striking infection-enhancing  ac- 
tion of hydrocortisone, it can be seen that hydrocortisone- 
treated  SCID  mice  inoculated  with  10  s  Erdman or  105 
H37Rv contained 1013'24 and 10  tz6~ organisms, respectively, 
in their lungs on day 25 of infection, compared with 10 ".75 
Erdman and  107.93 H37Rv  in  the lungs  of control  SCID 
mice. Hydrocortisone caused a similar increase in the numbers 
of virulent organisms in the lungs and other organs of CB- 
17 mice, but the absolute numbers reached by day 25 were 
considerably lower than those reached in the organs of SCID 
mice. The growth of BCG was also substantially increased 
in the organs of SCID and CB-17  mice  given hydrocorti- 
sone. Of particular interest, however, is the finding in Table 
1  showing that  hydrocortisone  caused an  increase in  the 
numbers of H37Ra in the organs of SCID and CB-17 mice. 
As shown in Fig. 4, this organism failed to grow progres- 
sively in any organ of control SCID mice. Therefore, the results 
with hydrocortisone  show that failure of H37Ra to grow 
1726  Mycobacterial  Virulence Table  1.  Enhancing Effect of Hydrocortisone on Mycobacteria Infection in SCID and CB-17 Mice (Log,o Bacteria~Organ on Day 25) 
Cortisone 
Mice  treatment  Strain  Lung  Kidney  Spleen  Liver 
SCID  -*  Erdman  11.75  _+  0.29  7.55  _+  0.11  12.51  _+  0.15  10.06  _+  0.14 
SCID  +  13.24  _+  0.08  10.59  _+  0.21  14.01  _+  0.14  14.00  +_  0.10 
CB17  -  9.41  _+  0.14  4.67  _+  0.18  7.93  _+  0.24  6.58  _+  0.18 
CB17  +  10.57  _+  0.09  5.33  _+  0.24  10.09  _+  0.22  7.63  _+  0.44 
SCID  -  H37Rv  7.93  +_  0.11  6.70  _+  0.32  9.80  _+  0.13  8.58  +_  0.11 
SCID  +  12.60  _+  0.23  9.45  _+  0.38  12.84  _+  0.12  12.30  _+  0.29 
CB17  -  5.10  _+  0.15  2.43  _+  0.10  7.24  +  0.14  4.88  _+  0.07 
CB17  +  8.64  +  0.14  3.41  +  0.25  10.21  +  0.15  6.01  _+  0.07 
SCID  -  H37Ka  4.48  _+  0.20  4.01  _+  0.10  7.19  _+  0.16  6.04  +  0.14 
SCID  +  5.36  +_  0.20  4.48  _+  0.16  9.10  +  0.15  9.01  _+  0.10 
CB17  -  3.84  +  0.08  1.81  +  0.26  4.66  +  0.09  4.34  +  0.08 
CB17  +  4.24  +  0.15  2.56  _+ 0.17  5.63  _+  0.18  5.41  +  0.22 
SCID  -  BCG  5.90  _+  0.13  5.70  _+  0.21  7.00  _+  0.09  6.90  _+  0.13 
SCID  +  8.00  _+  0.19  6.32  _+  0.37  7.72  _+  0.10  7.80  +  0.35 
CB17  -  5.40  _+  0.08  4.45  _+ 0.27  6.10  +  0.14  6.11  +  0.23 
CB17  +  6.20  _+  0.31  4.80  +  0.28  7.30  +  0.30  7.50  _+  0.02 
Mice were infected intravenously with los Erdman,  l0  s H37Rv,  106 H37Ra,  or  106 BCG. 
* 2.5  mg were given subcutaneously on days  10,  15,  and 20. 
progressively in SCID mice must be due to active growth 
inhibition by a cortisone-sensitive mechanism of resistance. 
The influence of this growth-restrictive mechanism on the 
growth of virulent and avirulent mycobacteria is best illus- 
trated in Table 2 which lists the doubling time of each strain 
in different organs of SCID and CB-17 mice treated or un- 
treated  with  hydrocortisone.  With  a  knowledge  of  the 
numbers of organisms on day 1 of infection,  the doubling 
times were obtained by calculating the number of times that 
each strain needed to divide (as a population) in order to reach 
the numbers present on day 25.  If it is assumed that SCID 
mice treated  with  hydrocortisone  offered no  resistance  to 
mycobacterial replication, then, it can be concluded that viru- 
lent organisms have a much shorter intrinsic doubling time 
in vivo than attenuated ones,  and that BCG has a shorter 
doubling time than H37Ra. Since the same ranking applies 
to doubling times measured in SCID control mice, it follows 
that virulent organisms are equipped to grow faster in the 
presence,  as well as in  the absence of this  hydrocortisone- 
sensitive defense mechanism. 
Growth Kinetics of  BCG in the Organs of  Hydrocortisone-treated 
Mice.  The foregoing results dearly show that SCID mice 
possess a glucocorticoid-sensitive mechanism that enables them 
to restrict the growth of virulent, as well as attenuated strains 
of mycobacteria, as evidenced by a faster rate of growth of 
all strains in all organs of SCID mice treated with hydrocor- 
tisone.  However, because these results were obtained on a 
single day of infection, it was considered important to deter- 
mine the effect of giving hydrocortisone on the kinetics of 
mycobacterial growth over a relatively long period of infec- 
tion.  This was done by following the growth of BCG in 
untreated and hydrocortisone-treated SCID and CB-17 mice 
inoculated intravenously with 2  x  106 BCG. In this experi- 
ment hydrocortisone was given every 5 d of infection begin- 
ning on day 15. Day 15 was chosen to start hydrocortisone 
treatment in this experiment, and day 10 in the preceding 
experiments, because an ongoing histological study (North, 
R. J., and A. Izzo, manuscript in preparation) shows that 
by these times of infection, BCG is already in macrophages 
in developing granulomas in the livers and spleens of SCID 
and CB-17 mice. As can be seen in Figs. 6 and 7, hydrocorti- 
sone treatment caused a substantial increase in the rate of BCG 
growth in all organs of SCID and CB-17 mice between days 
15 and 40 of infection, with the largest increase occurring 
in the lungs. It can also be seen that the rate of BCG growth 
in hydrocortisone-treated SCID mice was faster and more ex- 
tensive than in hydrocortisone-treated CB-17 mice. 
The purpose of the micrographs depicted in Figs.  8-10 is 
to show the consequences of hydrocortisone treatment on 
the cellular events at loci of infection in the livers of SCID 
mice. The results of a more extensive ongoing histological 
study of the consequences of hydrocortisone treatment on 
1727  North and lzzo Table  2.  Doubling  Times of  Mycobacteria Populations in Different Organs of  SCID and CB-I7 Mice Untreated or Treated with Hydrocortisone 
Cortisone 
Mice  treatment  Strain  Lung  Kidney  Spleen  Liver 
h 
SCID  -  *  Erdman  21.0  34.4  21.4  36.4 
SCID  +  17.7  21.4  18.0  19.9 
CB17  -  28.3  70.2  48.0  135.5 
CB17  +  24.0  55.9  30.0  77.8 
SCID  -  H37Rv  32.0  32.1  23.8  38.9 
SCID  +  17.4  21.3  16.7  21.1 
CB17  -  64.2  168.4  35.7  197.2 
CB17  +  27.8  86.3  22.2  86.3 
SCID  -  H37Ra  197.2  423.5  58.1  NC 
SCID  +  98.6  198.6  35.5  55.9 
CB17  -  321.7  NC*  NC  NC 
CB17  +  184.6  NC  187.0  NC 
SCID  -  BCG  96.3  91.2  133.6  157.8 
SCID  +  44.6  68.8  85.8  86.7 
CB17  -  102.1  231.3  248.2  NC 
CB17  +  69.3  157.8  91.4  123.8 
Doubling times determined from a knowledge of bacteria present in each organ on day I of intravenous  infection and on day 25 
* Cortisone given as for Table  1. 
* Not calculated (NC) because the number of bacteria  on day 25  was no greater  than on day  1. 
as shown in Table 1. 
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Figure  6.  Growth  of BCG in the lungs, kidneys, spleens, and livers 
of SCID mice and SCID mice treated  with 2.5 mg of hydrocortisone  ace- 
tate (SCID + CORT) at 5-d intervals beginning on day 15 of infection 
initiated with 5 x  10  s BCG i.v. Means of five mice per group per time 
interval. 
the appearance of infectious loci in different organs of SCID 
and CB-17 mice will be the subject of a forthcoming publi- 
cation (North, R. J., and A. Izzo, manuscript in prepara- 
tion). It can be seen in Figs. 8-10 that in the livers of control 
SCID mice, BCG was confined to discrete loci of infection 
that were occupied predominantly by epithelioid macrophages 
some of which contained BCG. The effect of giving hydrocor- 
tisone over a 20-d period was to permit a great deal more 
BCG multiplication to occur in epithelioid macrophages, to 
the extent that the cytoplasm of these cells became replete 
with bundles of bacilli. 
Discussion 
Tuberculosis  is a major world disease that no longer is 
confined to developing countries, but is now a public health 
threat in major U.S. cities primarily because of its high inci- 
dence in HIV-infected persons (14, 15) who can offer little 
resistance  to its progression.  Consequently, AIDS patients 
are serving as a reservoir  for an infectious agent that is not 
opportunistic, but capable of infecting and causing progres- 
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Figure  7.  Growth  of BCG in the lungs, kidneys, spleens, and livers 
of CB-17 mice and CB-17 mice treated with hydrocortisone  as described 
for Fig. 6. The experiment was done concurrently  with that shown by 
Fig. 6. Means of five mice per group per time interval. 
sive disease in a considerable  proportion of normal people. 
The problem is being made worse by the increasing incidence 
of the disease caused by drug-resistant strains of M. tubercu- 
losis (16). This situation has served to create  a sense of ur- 
gency towards developing drugs  to  treat  the disease  and 
designing vaccines to protect against contracting it. Currently, 
the only available antituberculosis vaccine is BCG, which, 
according to a number of trials (8), is of  limited value in pro- 
tecting adults against pulmonary tuberculosis. This has led 
to the suggestion (8,  9)  that more immunogenic vaccines 
be developed,  possibly with the aid of recombinant DNA 
technology. This might allow BCG to be provided with the 
capacity to express more immunogens, including those that 
are peculiar to virulent M. tuberculosis itself (8). However, it 
would seem  premature at this stage to begin the task of 
designing a better BCG vaccine without knowing whether 
lack of immunogenicity is the reason for its limited efficacy. 
It remains possible, until shown otherwise, that the pathoge- 
nicity of virulent mycobacteria is based on a capacity to resist 
destruction by relatively high levels of immunity generated 
in response  to BCG or M. tuberculosis itsdf. It is reasonable 
to suggest that the rational design of a better antitubercu- 
losis  vaccine  will require,  among other things,  an under- 
standing of mycobacterial virulence. 
Figure 8.  Low-power  micrographs  of  a BCG-infected  liver  of  a SCID mouse  (a) and a SCID mouse  treated  at 5-d intervals  with 2.5 mg of  hydrocorti- 
sone (b). Infection  was initiated  35 d earlier as described for Figs. 6 and 7. Granulomas  are obvious, and are bigger in hydrocortisone-treated  mice. 
Section was stained with phenol-crystal  violet. Bar, 100 #m. 
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of two standard virulent strains of M.  tuberculosis (Erdman 
and H37Rv) for mice is based on the ability of these strains 
to grow progressively in the lungs in the face of a systemic 
mechanism of acquired CD4  T  cell-dependent immunity 
capable of inhibiting mycobacterial growth in the liver, spleen, 
and kidneys. Attenuated strains (BCG and H37Ra), in con- 
trast, are shown to be incapable of causing progressive infec- 
tion in any organ in immunocompetent mice. Instead, infec- 
tion with these organisms is slowly resolved after 2-3 wk 
of bacterial growth. It has been shown, previously, in this 
connection (2,  3), that resolution of BCG infection also is 
predominantly dependent on CD4 + T cells. It was not sur- 
prising to find, therefore, that BCG can grow progressively in 
the lungs and other organs of SCID mice, although fastest 
in the lungs. Thus, the attenuated organism is opportunistic 
in the absence of specific immunity, and it is known from 
a previous study (3) that it is capable of eventually killing 
SCID  mice. 
In view of these results, it was not unexpected to find that 
virulent strains of M. tuberculosis also grew rapidly and pro- 
gressively in all organs of SCID mice, compared to only in 
the lungs of CB-17 mice. Moreover growth of these strains 
was fastest in the lungs of SCID mice, meaning that the lungs 
offer less resistance than other organs to the growth of viru- 
lent mycobacteria both in the absence and presence of specific 
immunity. Again, virulent strains grew much faster than BCG 
in all organs of SCID mice. Thus, since SCID mice are known 
to be devoid of immunologically dependent mycobacteria 
growth-restrictive mechanisms, it may be concluded that the 
major difference between virulent and attenuated mycobac- 
teria is that the former have much faster doubling times in 
vivo in the absence of acquired specific immunity. It could 
be suggested on the basis of the results presented, moreover, 
that growth of H37Ra is eventually self-limiting because its 
numbers in all organs of SCID mice is controlled after 2-3 
wk of infection. 
However, the results obtained with hydrocortisone clearly 
show that growth of H37Ra is not self-limiting in SCID 
mice, in that this organism grew to much larger numbers 
(1-3 log, depending on the organ) over a 25-d period of SCID 
mice treated with glucocorticoid. Therefore, growth of H37Re 
in SCID mice is controlled by a ghcocorticoid-sensitive mech- 
anism of antimycobacterial resistance that almost certainly 
is based on macrophage function. This can be suggested on 
the basis  of results of a histological study still  in progress 
(North,  R.  J.,  and  A.  Izzo,  manuscript  in  preparation) 
showing that it is in macrophages that H37Ra (and other 
strains under study here) resides during the course of infec- 
tion both in SCID and CB-17 mice. Indeed, it is shown here 
with BCG that this organism resides in macrophages of granu- 
lomas in the livers of SCID mice, and that the effect of giving 
hydrocortisone was to greatly increase the bacillary load in 
individual macrophages. It has been demonstrated (12, 13), 
in keeping with this interpretation, that glucocorticoids can 
inhibit the ability of macrophages to control the growth of 
certain microbial pathogens in vitro. Regardless of its iden- 
tity, this mycobacteria growth-restrictive mechanism also func- 
tions to retard the growth of virulent mycobacteria in SCID 
mice, as evidenced by a striking increase in the growth of 
these organisms in all  organs of SCID  mice treated with 
hydrocortisone. Given that it is likely that in the absence of 
this hydrocortisone+sensitive mechanism SCID mice can exert 
little, if any, active growth-restrictive influence on either at- 
tenuated or virulent mycobacteria, the growth rates of viru- 
lent and attenuated mycobacteria in hydrocortisone-treated 
SCID mice is probably a reflection of their true, intrinsic dou- 
bling times in vivo. Thus, the minimum doubling times in 
the lung (the organ in which all mycobacteria under study 
grow fastest) for Erdman, H371%, BCG, and H37Ra (Table 
2) are 17.7,  17.4,  44.6,  and 98.6 h, respectively.  The same 
ranking can be given to the doubling times of these strains 
in other organs of SCID mice treated with hydrocortisone. 
In view of these results, it seems reasonable to conclude 
that the ability to multiply faster in macrophages in vivo is 
a key characteristic that enables virulent mycobacteria to cause 
progressive infection in the lungs of immunocompetent mice 
in the face of a systemic mechanism of specific antimycobac- 
terial immunity capable of controlling the growth of these 
organisms in other organs. It is apparent that the antimycobac- 
terial function of macrophages in the liver, spleen, and kidneys, 
but not in the lungs, is sufficiently upregulated by specific 
immunity to control infection caused by virulent organisms. 
On the other hand, the antimycobacterial function of lung 
macrophages is sufficiently upregulated by specific immunity 
to control the growth of BCG in the lungs. It may well be 
asked, therefore, whether BCG could overcome the expres- 
sion of specific immunity in the lungs if it had a faster in- 
trinsic doubling time? Obviously, an answer to this ques- 
tion cannot be given at this time. However, an examination 
of the BCG growth curves presented here, and other BCG 
curves recently obtained in this laboratory (North, R.J., and 
A. Izzo, manuscript in preparation) leads one to believe that 
this might be the case. For example, the extent of growth 
of BCG in the lungs of immunocompetent mice is greater 
than its growth in other organs, because it takes longer for 
Figure 9.  Light  micrograph  of infectious  focus  in the liver of a control SCID mouse  infected  intravenously  35 d earlier with 2 x  10  + BCG. The 
infectious focus is occupied  by a granuloma made up predominantly  of epithelioid macrophages, some of which contain BCG. Section  was stained 
with phenol crystal violet. Bar, 10/~m. 
Figure 10.  Light  micrograph  of infectious  loci in the liver of a SCID mouse infected  35 d earlier with 2 x  106 BCG, and treated at 5-d intervals 
with 2.5 mg of hydrocortisone  beginning on day 15. The epithelioid  cells that populate the granuloma  have  permitted  enormously  more BCG growth 
than the epithelioid  cells shown in Fig. 8 for control SCID mice. The bundles of bacilli shown in the infectious  focus are confined  to areas representing 
the cytoplasm  of  epithelioid  macrophages,  some  of  which  have  been  sectioned  to include  a nucleus.  Section  was stained  with phenol-crystal  violet. Bar, 10/~m. 
1731  North and Izzo specific immunity to control the growth of BCG in the lungs. 
In addition, BCG grows faster in the lungs than in other 
organs of SCID mice, and it grows progressively in the lungs, 
but not in other organs, of athymic nude mice and euthymic 
mice depleted of CD4 + and CD8 + T  cells  (3). 
Not that mycobacterial virulence will be easy to explain 
mechanistically purely on the basis of a faster intrinsic dou- 
bling time. It is difficult to believe, for example, that a faster 
doubling time enables an organism to escape immune de- 
struction simply by enabling it to outgrow a developing im- 
mune response in the lungs. Rather, it seems more likely that 
the reason for escape from immunity will prove more com- 
plicated. For instance, a faster doubling time could result in 
some of the macrophages in which virulent mycobacteria im- 
plant becoming rapidly overloaded with bacilli to the extent 
of being rendered incapable of processing and presenting an- 
tigen. This would serve to make mycobacteria in these mac- 
rophages invisible to mycobacteria-specific T cells that need 
to see processed mycobacterial antigens at the surface of mac- 
rophages in the context of class II MHC in order to be stimu- 
lated to secrete macrophage-activating lymphokines. Needless 
to say, this implies that lung macrophages are heterogeneous 
with respect to origin and functional maturity. It also seems 
likely that the requirements for the expression of antimycobac- 
terial  immunity by macrophages may involve more than 
lymphokine-mediated upregulation of a single intramacro- 
phage mycobacteriacidal mechanism. The finding presented 
here which shows that hydrocortisone treatment failed to allow 
mycobacteria to grow as fast in CB-17 mice as in SCID mice 
points to the possibility that macrophages in the former mice 
acquire  a  microbicidal  mechanism in  association  with  T 
cell-mediated immunity which is resistant to glucocorticoid 
treatment. According to this line of reasoning, macrophages 
of immunocompetent mice would come to possess two sep- 
arate antimycobacterial mechanisms: a preexisting cortisone- 
sensitive  mechanism,  as  possessed  by  SCID  mice,  and  a 
cortisone-resistant mechanism that is brought into play by 
specific immunity. 
Published evidence in keeping with this idea is seen in the 
demonstration (13) that the baseline ability of human blood 
monocyte-derived macrophages to inactivate ingested Listeria 
monocytogenes in vitro can be abolished by exposing the mac- 
rophages to glucocorticoids. In contrast, the elevated listeri- 
acidal function acquired by these macrophages in response 
to treatment with IFN-3~ is resistant to treatment with glu- 
cocorticoids. Again, it has been shown (12) that the ability 
of mouse macrophages to inhibit the growth of ingested Toxo- 
plasma gondii trophozoites is severely suppressed by glucocor- 
ticoids,  but  not  if the macrophages are first  activated by 
lymphokines.  Presumably  a  similar  cortisone-resistant, 
macrophage-based mierobicidal or microbistatic mechanism 
needs to be acquired in order for mice to control the growth 
of virulent M. tuberculosis. Needless to say, this mechanism 
is not acquired by all macrophages in the lung during the 
course of infection with virulent M. tuberculosis. For this reason, 
the efficacy of an antimycobacterial vaccine needs to be judged 
on its ability to protect against the growth of viruhnt mycobac- 
teria in the lungs. According to published studies (6, 7), BCG 
is highly efficient at immunizing the lungs of mice against 
subsequent challenge with virulent organisms, provided the 
BCG is inoculated intravenously, or given by aerosol.  How- 
ever, the results of an ongoing study in this laboratory (North, 
R.J., and A. Izzo, manuscript in preparation) suggests that 
the protection afforded by BCG vaccination is not absolute, 
in that initial destruction of most of the virulent challenge 
organisms in the lungs is followed by regrowth of surviving 
organisms after a protracted period of time. It seems pos- 
sible, therefore, that regrowth of the challenge organism occurs 
is a small number of lung macrophages that is refractory to 
the activating signals of lymphokines secreted by specific T 
cells. 
The authors wish to thank Linda Schaefer,  Debbie Duso, Lynn Ryan, and Ron LaCourse for expert tech- 
nical assistance; and Mary Durett for typing. 
This work was supported by grant IHP-24 from the Trudeau Institute. 
Address correspondence to Dr. Robert J. North, Trudeau Institute, Inc., P.O. Box 59, Saranac Lake, NY 
12983. 
Received for publication 18 February 1993. 
References 
1.  Pierce, C.H., R.J. Dubos, and W.B. Schaefer. 1953. Multipli- 
cation and survival of tubercle bacilli in the organs of mice. 
J. EXla Med. 97:189. 
2.  Pedrazzini, T., K. Hug, and J.A. Louis. 1987. Importance of 
L3T4 § and Ly-2  + cells in the immunogenic control of infec- 
tion with Mycobacteria boris strain Bacillus Calmette-Guerin 
1732  Mycobactefial  Virulence 
in mice.  J. Immunol. 139:2032. 
3.  Izzo, A.A., and R.J. North. 1992. Evidence for an c~/B T 
cell-independent mechanism of resistance to Mycobacteria.  Ba- 
cillus Calmette-Guerin infection causes progressive infection 
in severe combined immunodeficient mice, but not in nude 
mice or mice depleted of CD4 + and CD8 + T cells. J. Exl~ Med.  176:581. 
4.  Orme, I.M. 1988. Evidence for biphasic memory T-cell-response 
to high dose BCG vaccination in mice. Tubercle. 69:125. 
5.  Leveton, C., S. Barnass,  B. Champion, S. Lucas, B. DeSousa, 
M. Nicol, D. Banerjee,  and G. Rook. 1989. T cell-mediated 
protection of mice against virulent Mycobacterium tuberculosis. 
Infect. Immun.  57:390. 
6.  Larson, C.L., and W.C. Wicht.  1962. Studies of resistance to 
experimental tuberculosis in mice vaccinated with living at- 
tenuated tubercle bacilli and challenged with virulent organisms. 
Am.  Rev. Respir. Dis.  85:833. 
7.  Lefford, M.J. 1977. Induction and expression of immunity after 
BCG immunization. Infect. Immun.  18:646. 
8.  Bloom,  B.R.,  and  W.R.  Jacobs.  1989.  New  strategies  for 
leprosy  and  tuberculosis  and  for  development  of Bacillus 
Calmette-Guefin into a multivaccine vehicle. Ann. NY. Acad. 
Sci. 569:155. 
9.  Kaufmann, S.H.E. 1990. Vaccines against tuberculosis:  the im- 
pact of modern biotechnology. Scand.J. Infect. Dis. Surf. 76:54. 
10.  Harmsen, A.G., and M. Stankiewicz. 1990. Requirements for 
CD4 § cells in resistance to Pneumocystis carinii pneumonia in 
mice. f  Ext~ Med.  172:937. 
11.  Lechtman, M.D., J.W. Bartholomew, A. Phillips, and M. Russo. 
1965. Rapid method for staining bacterial spores at room tem- 
perature. J. Bacteriol. 89:848. 
12.  Masur,  H.,  H.W.  Murray,  and  T.C. Jones.  1982.  Effect of 
hydrocortisone on macrophage response to lymphokine. Infect. 
Immun.  35:709. 
13.  Schaffner, A. 1985. Therapeutic concentrations for glucocor- 
ticoids suppress  the antimicrobial activity of human macro- 
phages without impairing their responsiveness  to gamma in- 
terferon. J.  Clin.  Invest. 76:1755. 
14.  Centers for Disease Control.  1991. Tuberculosis and human 
immunodeficiency virus infection.  Recommendations of the 
advisory committee for the elimination of tuberculosis (ACET). 
MMWR  (Moth  Mortal.  Wkly.  Retx  )  38:236. 
15.  Centers  for  Disease  Control.  1991. Tuberculosis  outbreak 
among persons in a residential facility for HIV-infected per- 
sons-San  Francisco.  MMWR  (Morh  Mortal.  Wkly.  Relx  ) 
40:649. 
16.  Centers for Disease Control.  1991. Nosocomial transmission 
of multidrug-resistant tuberculosis among HIV-infected per- 
sons-Florida  and  New  York,  1988-1991.  MMWR  (Moth 
Mortal.  l,  Vkly.  Retx  )  40:585. 
1733  North and Izzo 